Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Wu

Pulmonary Disease Huntington Woods, MI Medical Doctor

NPI 1740236652 CMS profile 169559

26657 Woodward Ave Ste 100, Huntington Woods, MI 48077

Open in the dashboard

General payments

$13,192

711 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Wu of Huntington Woods, MI is reported in the CMS Open Payments database as having received $13,192 across 711 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,518 129
2024 General $1,889 86
2023 General $2,067 107
2022 General $2,283 120
2021 General $1,620 95
2020 General $1,280 77
2019 General $1,534 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Wu
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to David Wu were reported at $2,518. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year David Wu Pulmonary Disease median Middle half National median
2019 $1,534 $377 $109–$1,340 $163
2020 $1,280 $230 $56–$907 $114
2021 $1,620 $269 $68–$1,072 $132
2022 $2,283 $390 $100–$1,457 $149
2023 $2,067 $419 $114–$1,659 $160
2024 $1,889 $476 $123–$1,818 $164
2025 $2,518 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,664 190 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $2,054 106 payments
  3. AstraZeneca Pharmaceuticals LP $1,583 91 payments
  4. Mylan Specialty L.P. $849 40 payments
  5. Grifols USA, LLC $714 29 payments
  6. Genzyme Corporation $559 31 payments
  7. Regeneron Healthcare Solutions, Inc. $539 28 payments
  8. Baxter Healthcare $470 15 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $434 23 payments
  10. Verona Pharma, Inc. $399 28 payments
  11. Other $2,927 130 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,113 710 payments
  2. Education $79 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,409 107 payments
  2. STIOLTO RESPIMAT $747 39 payments
  3. Prolastin-C Liquid $714 29 payments
  4. YUPELRI $701 31 payments
  5. SPIRIVA RESPIMAT $672 33 payments
  6. DUPIXENT Immunology $638 32 payments
  7. OFEV $596 32 payments
  8. NUCALA $594 36 payments
  9. DUPIXENT Inflammation And Immunology $461 24 payments
  10. GLASSIA $451 24 payments
  11. Other $8,125 403 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,102

Median for Pulmonary Disease: 936

Drug cost

$661,097

Median for Pulmonary Disease: $487,987

Branded share of claims

78.3%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 12 $261,040
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 159 $139,239
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 90 $50,926
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 62 $46,141
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 47 $35,835
Spiriva Respimat Tiotropium Bromide Brand 43 $29,899
Breo Ellipta Fluticasone/Vilanterol Brand 54 $29,222
Pirfenidone Generic 16 $20,557
Symbicort Budesonide/Formoterol Fumarate Brand 39 $14,115
Albuterol Sulfate Hfa Albuterol Sulfate Brand 221 $7,069

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$141,831

Medicare's payments for the services billed

Medicare patients

502

Average age 77

Services billed

2,216

282 women, 220 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 57%
Arthritis 57%
COPD 50%
Chronic kidney disease 40%
Heart failure 38%
Diabetes 36%
Atrial fibrillation 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$281 — —
OFEV
$227 12 —
TRELEGY ELLIPTA
$163 159 —
TEZSPIRE
$134 — —
YUPELRI
$129 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

711 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record